Recruiting

SurviVRSE

Sponsor:

Virginia Commonwealth University

Code:

NCT07426913

Conditions

Breast Cancer

Anthracycline Related Cardiotoxicity in Breast Cancer

Virtual Reality

Trastuzumab

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cardiovascular Health Education and Gaming through Virtual Reality

Study Details

Brief summary:

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).

Conditions

Breast Cancer

Anthracycline Related Cardiotoxicity in Breast Cancer

Virtual Reality

Trastuzumab

Study ID

NCT07426913

Start date

May 20, 2026

Status verified date

Jul, 2026

Completion date

Feb 28, 2027

Anticipated

Primary completion date

Jul 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years of age or older
  • Able to speak and read in English
  • Actively receiving Trastuzumab or an anthracycline-based treatment
  • Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.
  • Diagnosed with stages 0-III Breast Cancer

Exclusion Criteria:

\- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Virtual Reality Group

Individuals in this arm will receive access to the virtual reality in cardiovascular health education and gaming intervention

Interventions

Cardiovascular Health Education and Gaming through Virtual Reality

Prior to engaging the intervention, participants will complete a baseline survey. The virtual reality intervention will be delivered at one infusion treatment. Participants will complete all education modules and affiliated games. The education focuses on potentially cardiotoxic treatments (e.g., anthracyclines), ways to identify cancer treatment related cardiovascular dysfunction, and heart healthy behaviors that survivors can initiate during survivorship. Following the intervention participants will complete a survey similar to the baseline survey. One-month following the intervention participants will complete one final survey.

Primary outcome measure

  • CTRCD Knowledge [ Time Frame: Baseline, within 2 days post-Intervention, and 4 weeks post-intervention ]
  • Usability [ Time Frame: Within 2 days post-Intervention ]
  • Acceptability [ Time Frame: Within 2 days post-Intervention ]
  • User Satisfaction [ Time Frame: Within 2 days post-Intervention ]

Central Contacts and Locations

Central contacts

Arnethea Sutton, Ph.D

8048277363careslab@vcu.edu

Victoria Williams

8048277363williamsv4@vcu.edu

Locations

Adult Outpatient Pavilion

Recruiting

Richmond, Virginia, United States, 23220

Contacts

Victoria Williams

8048277363williamsv4@vcu.edu

Cellular Immunotherapies and Transplant Department

Recruiting

Richmond, Virginia, United States, 23220

Contacts

Victoria Williams

8048277363williamsv4@vcu.edu

VCU Health at Stony Point

Recruiting

Richmond, Virginia, United States, 23223

Contacts

Victoria Williams

8048277363williamsv4@vcu.edu

More Information

Sponsor

Virginia Commonwealth University

Last update posted

Jul 2, 2026

Last verified

Jul, 2026

Keywords

  • virtual reality
  • breast cancer
  • antracyclines
  • trastuzumab
  • VCU
  • Virginia Commonwealth University

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Virginia Commonwealth University on 2026-07-02.